InMed Pharmaceuticals (INM) Net Margin (2021 - 2025)
InMed Pharmaceuticals' (INM) quarterly Net Margin came in at 247.29% in Q4 2025, down 1566.0% year-on-year from 16.87% in Q4 2024, and down 60.4% quarter-over-quarter from 154.17% in Q3 2025.
InMed Pharmaceuticals (INM) Net Margin (2021 - 2025) Analysis & Trends
InMed Pharmaceuticals' Net Margin history runs 5 years deep, the most recent figure standing at 247.29% for Q4 2025.
- On a quarterly basis, Net Margin fell 1566.0% year-over-year to 247.29% in Q4 2025; TTM through Dec 2025 was 113.51%, a 5011.0% increase from a year earlier, with the FY2025 full-year figure at 165.14%, up 180.0% from the prior year.
- Net Margin eased to 247.29% in Q4 2025 per INM's latest filing, from 154.17% in the prior quarter.
- Across five years, Net Margin topped out at 4.27% in Q1 2025 and bottomed at 1615.6% in Q4 2021.
- The 5-year median for Net Margin is 193.09% (2023), against an average of 414.13%.
- Across the five-year window, Net Margin surged 151431 bps in 2023 and sank 13590 bps in 2024, its largest moves.
- Year by year, Net Margin stood at 1615.6% in 2021, then surged by 72 bps to 446.61% in 2022, then soared by 73 bps to 119.19% in 2023, then sank by 94 bps to 231.63% in 2024, then declined by 7 bps to 247.29% in 2025.
- Per Business Quant, the three latest INM Net Margin figures stand at 247.29% (Q4 2025), 154.17% (Q3 2025), and 100.13% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 9.29% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 26.57% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -33.66% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 35.18% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 5.03% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 24.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 4.16% |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -247.29% |
| Sep 30, 2025 | -154.17% |
| Jun 30, 2025 | -100.13% |
| Mar 31, 2025 | -4.27% |
| Dec 31, 2024 | -231.63% |
| Sep 30, 2024 | -132.68% |
| Jun 30, 2024 | -150.47% |
| Mar 31, 2024 | -146.93% |
| Dec 31, 2023 | -119.19% |
| Sep 30, 2023 | -281.29% |
| Jun 30, 2023 | -14.56% |
| Mar 31, 2023 | -193.09% |
| Dec 31, 2022 | -446.61% |
| Sep 30, 2022 | -1,094.24% |
| Jun 30, 2022 | -1,528.88% |
| Mar 31, 2022 | -579.28% |
| Dec 31, 2021 | -1,615.60% |